Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06285318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06285318 · ClinicalTrials.gov record · last posted 2026-07-31

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Study acronym: REALiTEC/TAL
StatusRecruiting
PhaseNot specified
Started2023-12-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Protocol amendment history 2 changes detected by DataLookout

2026-08-01
Primary completion pushed: 2026-06-30 → 2026-08-30
2026-05-09
Completion pushed: 2026-07-31 → 2026-09-24
Trial Details
NCT Number NCT06285318
Lead Sponsor Janssen-Cilag Ltd.
Conditions Relapsed/Refractory Multiple Myeloma (RRMM)
Enrollment 900 participants
Start Date 2023-12-18
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-09-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-31